JP2017528452A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017528452A5 JP2017528452A5 JP2017511233A JP2017511233A JP2017528452A5 JP 2017528452 A5 JP2017528452 A5 JP 2017528452A5 JP 2017511233 A JP2017511233 A JP 2017511233A JP 2017511233 A JP2017511233 A JP 2017511233A JP 2017528452 A5 JP2017528452 A5 JP 2017528452A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- pharmaceutical composition
- cancer
- composition according
- pkc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003112 inhibitor Substances 0.000 claims description 10
- 102000001892 Protein Kinase C-theta Human genes 0.000 claims description 3
- 108010015499 Protein Kinase C-theta Proteins 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 24
- 206010028980 Neoplasm Diseases 0.000 claims 14
- 201000011510 cancer Diseases 0.000 claims 13
- HKOWATVSFKRXRW-UHFFFAOYSA-N 4-n-[[4-(aminomethyl)cyclohexyl]methyl]-5-nitro-2-n-[[2-(trifluoromethoxy)phenyl]methyl]pyrimidine-2,4-diamine Chemical compound C1CC(CN)CCC1CNC1=NC(NCC=2C(=CC=CC=2)OC(F)(F)F)=NC=C1[N+]([O-])=O HKOWATVSFKRXRW-UHFFFAOYSA-N 0.000 claims 11
- 229940123628 Lysine (K)-specific demethylase 1A inhibitor Drugs 0.000 claims 7
- 229940124597 therapeutic agent Drugs 0.000 claims 7
- 230000035899 viability Effects 0.000 claims 6
- 239000012830 cancer therapeutic Substances 0.000 claims 5
- 206010027476 Metastases Diseases 0.000 claims 4
- 230000009401 metastasis Effects 0.000 claims 4
- 210000000130 stem cell Anatomy 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 3
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 238000012423 maintenance Methods 0.000 claims 2
- 208000037819 metastatic cancer Diseases 0.000 claims 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 2
- 230000035755 proliferation Effects 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000022131 cell cycle Effects 0.000 claims 1
- 230000032823 cell division Effects 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 210000002919 epithelial cell Anatomy 0.000 claims 1
- 230000012010 growth Effects 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000000683 nonmetastatic effect Effects 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- 230000000861 pro-apoptotic effect Effects 0.000 claims 1
- 239000002534 radiation-sensitizing agent Substances 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 description 7
- 125000003118 aryl group Chemical group 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 125000001072 heteroaryl group Chemical group 0.000 description 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 2
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 description 1
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2014903345 | 2014-08-25 | ||
| AU2014903345A AU2014903345A0 (en) | 2014-08-25 | Compositions for Modulating Cancer Stem Cells and Uses Therefor | |
| PCT/AU2015/050489 WO2016029262A1 (en) | 2014-08-25 | 2015-08-25 | Compositions for modulating cancer stem cells and uses therefor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020143429A Division JP2021001177A (ja) | 2014-08-25 | 2020-08-27 | がん幹細胞を調節するための組成物およびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017528452A JP2017528452A (ja) | 2017-09-28 |
| JP2017528452A5 true JP2017528452A5 (enExample) | 2018-07-19 |
Family
ID=55398499
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017511233A Pending JP2017528452A (ja) | 2014-08-25 | 2015-08-25 | がん幹細胞を調節するための組成物およびその使用 |
| JP2020143429A Pending JP2021001177A (ja) | 2014-08-25 | 2020-08-27 | がん幹細胞を調節するための組成物およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020143429A Pending JP2021001177A (ja) | 2014-08-25 | 2020-08-27 | がん幹細胞を調節するための組成物およびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10485772B2 (enExample) |
| EP (1) | EP3185858A4 (enExample) |
| JP (2) | JP2017528452A (enExample) |
| CN (1) | CN107106517A (enExample) |
| AU (1) | AU2015309686B2 (enExample) |
| CA (1) | CA2958704A1 (enExample) |
| SG (1) | SG11201701237QA (enExample) |
| WO (1) | WO2016029262A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI3381896T3 (fi) | 2015-11-27 | 2023-04-21 | Taiho Pharmaceutical Co Ltd | Bifenyyliyhdiste tai sen suola |
| JP7341451B2 (ja) * | 2016-02-01 | 2023-09-11 | エピアクシス セラピューティクス プロプライアタリー リミティド | タンパク質性化合物とその利用 |
| SG11201901624RA (en) * | 2016-09-07 | 2019-03-28 | Univ Canberra | Lysine specific histone demethylase-1 inhibitors and uses therefor |
| WO2018059549A1 (en) * | 2016-09-30 | 2018-04-05 | Novartis Ag | Immune effector cell therapies with enhanced efficacy |
| WO2018216795A1 (ja) * | 2017-05-26 | 2018-11-29 | 大鵬薬品工業株式会社 | 新規なビフェニル化合物を用いた抗腫瘍効果増強剤 |
| RU2765152C2 (ru) | 2017-05-26 | 2022-01-26 | Тайхо Фармасьютикал Ко., Лтд. | Новое соединение бифенила или его соль |
| AU2018276611B2 (en) | 2017-05-31 | 2022-01-06 | Taiho Pharmaceutical Co., Ltd. | Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 |
| CN111587120A (zh) * | 2017-11-08 | 2020-08-25 | 艾比克斯治疗私人有限公司 | 免疫原性组合物及其用途 |
| AU2018377852B2 (en) * | 2017-11-29 | 2022-03-24 | Epiaxis Therapeutics Pty Ltd | Enhancing T-cell function and treating a T-cell dysfunctional disorder with a combination of an LSD inhibitor and a PD1 binding antagonist |
| KR102125960B1 (ko) * | 2018-10-15 | 2020-06-25 | 한국생명공학연구원 | 세포 리프로그래밍 조성물 및 이를 이용한 유도만능줄기세포의 제조방법 |
| MX2022005811A (es) | 2019-11-13 | 2022-06-08 | Taiho Pharmaceutical Co Ltd | Sal novedosa de compuesto de terfenilo. |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3365458A (en) | 1964-06-23 | 1968-01-23 | Aldrich Chem Co Inc | N-aryl-n'-cyclopropyl-ethylene diamine derivatives |
| US3532749A (en) | 1965-05-11 | 1970-10-06 | Aldrich Chem Co Inc | N'-propargyl-n**2-cyclopropyl-ethylenediamines and the salts thereof |
| US3471522A (en) | 1967-09-29 | 1969-10-07 | Aldrich Chem Co Inc | N-cyclopropyl-n'-furfuryl-n'-methyl ethylene diamines |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| US5804604A (en) | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
| ATE318832T1 (de) | 1990-06-11 | 2006-03-15 | Gilead Sciences Inc | Verfahren zur vervendung von nukleinsäureliganden |
| US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
| ATE237694T1 (de) | 1991-08-20 | 2003-05-15 | Us Gov Health & Human Serv | Adenovirus vermittelter gentransfer in den gastrointestinaltrakt |
| US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| EP0673431A1 (en) | 1992-12-03 | 1995-09-27 | Genzyme Corporation | Gene therapy for cystic fibrosis |
| EP0705344B8 (en) | 1993-06-24 | 2006-05-10 | Advec Inc. | Adenovirus vectors for gene therapy |
| DE69435223D1 (de) | 1993-10-25 | 2009-09-03 | Canji Inc | Rekombinanter Adenoviren-Vektor und Verfahren zur Verwendung |
| US5783405A (en) | 1994-02-01 | 1998-07-21 | Terrapin Technologies, Inc. | Rapid screening method for effectors of signal transduction |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| CA2242425C (en) | 1996-02-13 | 2006-07-18 | Zeneca Limited | Quinazoline derivatives as vegf inhibitors |
| NZ331191A (en) | 1996-03-05 | 2000-03-27 | Zeneca Ltd | 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| US20030073640A1 (en) | 1997-07-23 | 2003-04-17 | Ribozyme Pharmaceuticals, Inc. | Novel compositions for the delivery of negatively charged molecules |
| CA2326823A1 (en) | 1998-04-20 | 1999-10-28 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid molecules with novel chemical compositions capable of modulating gene expression |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| US20050020525A1 (en) | 2002-02-20 | 2005-01-27 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| US8202979B2 (en) | 2002-02-20 | 2012-06-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid |
| KR20080023768A (ko) | 2000-03-30 | 2008-03-14 | 화이트헤드 인스티튜트 포 바이오메디칼 리서치 | Ｒｎａ 간섭의 ｒｎａ 서열 특이적인 매개체 |
| BR0111230A (pt) | 2000-05-31 | 2003-06-10 | Astrazeneca Ab | Composto, e, uso e processo para a preparação do mesmo |
| KR20030014425A (ko) | 2000-07-07 | 2003-02-17 | 앤지오젠 파마슈티칼스 리미티드 | 혈관 손상제인 콜치놀 유도체 |
| EE200300015A (et) | 2000-07-07 | 2004-10-15 | Angiogene Pharmaceuticals Limited | Kolhinooli derivaadid kui angiogeneesi inhibiitorid |
| ATE506372T1 (de) | 2000-09-01 | 2011-05-15 | Ribozyme Pharm Inc | Verfahren zur herstellung von nukleosidderivate |
| US20020150936A1 (en) | 2000-09-01 | 2002-10-17 | Leonid Beigelman | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives |
| CN100523215C (zh) | 2000-12-01 | 2009-08-05 | 马普科技促进协会 | 介导rna干涉的小rna分子 |
| US20050282188A1 (en) | 2001-05-18 | 2005-12-22 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) |
| US20050239731A1 (en) | 2001-05-18 | 2005-10-27 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of MAP kinase gene expression using short interfering nucleic acid (siNA) |
| JP2005523326A (ja) | 2002-04-22 | 2005-08-04 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ | プロテインキナーゼｃのペプチドインヒビター |
| WO2003106451A1 (en) | 2002-06-14 | 2003-12-24 | Altana Pharma Ag | Substituted diaminopyrimidines |
| EP1590334B1 (en) | 2003-01-30 | 2009-08-19 | Boehringer Ingelheim Pharmaceuticals Inc. | 2,4-diaminopyrimidine derivatives useful as inhibitors of pkc-theta |
| JP2007509185A (ja) | 2003-10-27 | 2007-04-12 | ノバルティス アクチエンゲゼルシャフト | βアミロイド産生および／または凝集と関係がある神経障害および血管障害の処置のためのインドリル−ピロールジオン誘導体 |
| US20050187156A1 (en) | 2003-12-11 | 2005-08-25 | Daria Mochly-Rosen | Isozyme-specific antagonists of protein kinase C |
| TW200533357A (en) | 2004-01-08 | 2005-10-16 | Millennium Pharm Inc | 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases |
| ATE432260T1 (de) | 2005-03-28 | 2009-06-15 | Boehringer Ingelheim Int | Pyridinderivate als pkc-theta-hemmer |
| EP1940773B1 (en) | 2005-08-10 | 2015-03-18 | Johns Hopkins University | Polyamines useful as anti-parasitic and anti-cancer therapeutics and as lysine-specific demethylase inhibitors |
| AU2007309167A1 (en) * | 2006-10-20 | 2008-05-02 | N.V. Organon | Purines as PKC-theta inhibitors |
| MX2011000837A (es) | 2008-07-23 | 2011-04-05 | Vertex Pharma | Inhibidores de pirazolpiridina cinasa triciclica. |
| MX2011001319A (es) | 2008-08-06 | 2011-04-05 | Vertex Pharma | Inhibidores de aminopiridina cinasa. |
| US8436025B2 (en) | 2008-09-19 | 2013-05-07 | CompleGen Partners, Inc. | Compounds and methods for PKC theta inhibition |
| WO2010043721A1 (en) | 2008-10-17 | 2010-04-22 | Oryzon Genomics, S.A. | Oxidase inhibitors and their use |
| CN102292333B (zh) | 2009-01-15 | 2015-05-13 | 里格尔药品股份有限公司 | 蛋白激酶c抑制剂及其用途 |
| US8993808B2 (en) | 2009-01-21 | 2015-03-31 | Oryzon Genomics, S.A. | Phenylcyclopropylamine derivatives and their medical use |
| EP3361368B1 (en) | 2009-06-10 | 2021-02-17 | Hexagon Technology Center GmbH | Ontological filtering using spatial boundary of 3d objects |
| EP2528917B1 (en) * | 2010-01-27 | 2016-10-19 | Vertex Pharmaceuticals Incorporated | Pyrazolopyridines useful for the treatment of autoimmune, inflammatory or (hyper)proliferative diseases |
| MX2012008642A (es) | 2010-01-27 | 2012-11-23 | Vertex Pharma | Inhibidores de cinasas de pirazolopiridinas. |
| RS55348B1 (sr) | 2010-04-19 | 2017-03-31 | Oryzon Gnomics S A | Inhibitori lizin specifične demetilaze-1 i njihova upotreba |
| WO2012009475A1 (en) * | 2010-07-14 | 2012-01-19 | Oregon Health & Science University | Methods of treating cancer with inhibition of lysine-specific demethylase 1 |
| DK2598482T3 (en) | 2010-07-29 | 2018-06-14 | Oryzon Genomics Sa | ARYLCYCLOPROPYLAMINE-BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE |
| EP2598480B1 (en) | 2010-07-29 | 2019-04-24 | Oryzon Genomics, S.A. | Cyclopropylamine derivatives useful as lsd1 inhibitors |
| WO2012034116A2 (en) | 2010-09-10 | 2012-03-15 | The Johns Hopkins University | Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders |
| UY34072A (es) | 2011-05-17 | 2013-01-03 | Novartis Ag | Derivados sustituidos de indol |
| BR112014002939A2 (pt) | 2011-08-09 | 2017-03-01 | Takeda Pharmaceuticals Co | composto, medicamento, método para profilaxia ou tratamento de doença, a doença sendo esquizofrenia, alzheimer, parkinson ou huntington, uso do composto, e, método para inibir o lsd1 |
| US9266838B2 (en) | 2011-08-15 | 2016-02-23 | University Of Utah Research Foundation | Substituted (E)-N′-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhibitors |
| US9289415B2 (en) | 2011-09-01 | 2016-03-22 | The Brigham And Women's Hospital, Inc. | Treatment of cancer |
| WO2014084298A1 (ja) * | 2012-11-28 | 2014-06-05 | 京都府公立大学法人 | リシン構造を有するｌｓｄ1選択的阻害薬 |
| US9144555B2 (en) | 2012-11-30 | 2015-09-29 | Darlene E. McCord | Hydroxytyrosol and oleuropein compositions for induction of DNA damage, cell death and LSD1 inhibition |
| SG11201510369WA (en) | 2013-06-25 | 2016-01-28 | Univ Canberra | Methods and compositions for modulating cancer stem cells |
| CA2923765C (en) | 2013-09-18 | 2021-06-29 | University Of Canberra | Stem cell modulation ii |
-
2015
- 2015-08-25 AU AU2015309686A patent/AU2015309686B2/en active Active
- 2015-08-25 WO PCT/AU2015/050489 patent/WO2016029262A1/en not_active Ceased
- 2015-08-25 SG SG11201701237QA patent/SG11201701237QA/en unknown
- 2015-08-25 US US15/506,469 patent/US10485772B2/en active Active
- 2015-08-25 CA CA2958704A patent/CA2958704A1/en not_active Abandoned
- 2015-08-25 CN CN201580054149.0A patent/CN107106517A/zh active Pending
- 2015-08-25 EP EP15835730.1A patent/EP3185858A4/en not_active Withdrawn
- 2015-08-25 JP JP2017511233A patent/JP2017528452A/ja active Pending
-
2019
- 2019-11-13 US US16/682,170 patent/US20200289437A1/en not_active Abandoned
-
2020
- 2020-08-27 JP JP2020143429A patent/JP2021001177A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013503139A5 (enExample) | ||
| JP2016538344A5 (enExample) | ||
| CO2019011762A2 (es) | Compuestos que inhiben la proteína mcl-1 | |
| SI2970216T1 (en) | Biaryl-amide compounds as kinase inhibitors | |
| RU2020102453A (ru) | Фармацевтические композиции | |
| ECSP066833A (es) | Compuestos heterocíclicos anticitocina | |
| RS59622B1 (sr) | Novi amonijum derivati, postupak za njihovo dobijanje i farmaceutske kompozicije koje ih sadrže | |
| EA201790595A1 (ru) | Пиримидиноны в качестве ингибиторов фактора xia | |
| KR20180019223A (ko) | 신규한 하이드록시에스테르 유도체, 이들의 제조 방법 및 이들을 함유하는 약학적 조성물 | |
| JP2016505621A5 (enExample) | ||
| EA201170617A1 (ru) | Пиразолиламинопиридины в качестве ингибиторов fak | |
| JP2011509949A5 (enExample) | ||
| UY33587A (es) | Nuevos compuestos como inhibidores de quinasas syk y jak | |
| PH12014500987A1 (en) | Neprilysin inhibitors | |
| PH12019502605A1 (en) | Glucuronide prodrugs of janus kinase inhibitors | |
| JP2012504628A5 (enExample) | ||
| JP2015512943A5 (enExample) | ||
| MX390748B (es) | Composiciones y metodos para tratar accidente cerebrovascular isquemico. | |
| WO2019090090A1 (en) | Modulators of the integrated stress pathway | |
| EA201291246A1 (ru) | Конденсированные бициклические ингибиторы киназы | |
| MX2016015435A (es) | Combinacion farmaceutica que comprende un inhibidor de quinasa de tirosina del receptor clase iii y la molecula de fusion inhibidora de deacetilasa de histona alquilante edo-s101 y su uso en el tratamiento de cancer. | |
| CN110305126A (zh) | 一种基于crbn配体诱导cdk4/6降解的化合物及其制备方法、药物组合物和应用 | |
| SI3174881T1 (en) | (1,2,4) triazolo (4,3-B) pyridazines for use in the treatment of proliferative diseases | |
| EP4602044A1 (en) | Substituted 3,7-dihydro-1 h-purine-2,6-diones and use thereof | |
| CA3130003C (en) | 2-benzoylaminobenzamide derivatives as bcl-3 inhibitors |